Modulation of PPAR subtype selectivity. Part 2: Transforming PPARα/γ dual agonist into α selective PPAR agonist through bioisosteric modification
作者:Pandurang Zaware、Shailesh R. Shah、Harikishore Pingali、Pankaj Makadia、Baban Thube、Suresh Pola、Darshit Patel、Priyanka Priyadarshini、Dinesh Suthar、Maanan Shah、Jeevankumar Jamili、Kalapatapu V.V.M. Sairam、Suresh Giri、Lala Patel、Harilal Patel、Hareshkumar Sudani、Hiren Patel、Mukul Jain、Pankaj Patel、Rajesh Bahekar
DOI:10.1016/j.bmcl.2010.12.032
日期:2011.1
A novel series of oxime containing benzyl-1,3-dioxane-r-2-carboxylic acid derivatives (6a–k) were designed as selective PPARα agonists, through bioisosteric modification in the lipophilic tail region of PPARα/γ dual agonist. Some of the test compounds (6a, 6b, 6c and 6f) showed high selectivity towards PPARα over PPARγ in vitro. Further, highly potent and selective PPARα agonist 6c exhibited significant
肟的含苄基-1,3-恶烷的新型系列ř -2-羧酸衍生物(6A - ķ)被设计为选择性PPAR α中的PPAR亲脂性尾部区域激动剂,通过生物电子等排修饰α / γ双重激动剂。一些测试化合物(的图6a,图6b,图6c和图6f)表现出较高的选择性向PPAR α超过PPAR γ体外。此外,高度有效的和选择性PPAR α激动剂6C在体内表现出显着的降血糖和降血脂活性,以及改善的药代动力学特征。的有利在-硅片相互作用6C与PPAR α结合口袋归属关系朝其体外选择性分布PPAR α超过PPAR γ。总之,这些结果证实的新颖系列肟基于选择性PPAR的发现α关于各种代谢紊乱的安全有效的治疗激动剂。